Company* (Country; Symbol)


Type/Product Area

Terms/Details (Date)

Codexis Inc.*

Shell Oil Products US

Collaboration to explore enhanced methods of converting biomass to biofuels

Codexis will use its biocatalytic approach in the effort; terms of the deal were not disclosed (11/16)

Dyadic International Inc. (AMEX:DIL)

Abengoa Bioenergy R&D Inc.

Deal to develop a cost-effective enzyme production system in Abengoa's bioethanol production process

Abengoa is purchasing 2.136M shares of Dyadic for $10M; Dyadic also may be entititled to license fees, technology transfer fees and royalties under the three-year deal (10/27)

Ortec International Inc. (OTC BB:OTCI)

Paul Capital Healthcare

They amended 2001 deal covering future Orcel-related revenue

Paul Capital is exchanging its interest in OrCel-related revenue for $10M in Ortec convertible preferred stock (11/29)

Perfusion Therapeutics Inc.* (Canada)

Covalon Technologies Ltd. (Canada)

Covalon completed its acquisition of Perfusion's endothelial PAS domain protein 1-based gene therapy technology

Perfusion is entitled to receive up to 1.1M Covalon shares based on various milestones; the cell engineering platform is being developed for improving blood vessel development (10/24)


* Private companies are indicated with an asterisk.

Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market.

AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board.